EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma

Alexander F Haddad, Rithvik Ramesh, Jorge Armando Peña Agudelo, Christopher Salha, Pranav Prakash, Shreya R Aghi, James S Trippett, Maria G Castro, Manish K Aghi

JAMA Neurology · 2026

DOI: 10.1001/jamaneurol.2026.2131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA Neurology, 2026. Verfasst von Alexander F Haddad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California, San Francisco. Hauptthemen laut MEDLINE: Glioblastoma, Genetic Therapy, Brain Neoplasms, Gene Transfer Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glioblastoma (GBM) remains a disease with high mortality despite treatment with maximal safe surgical resection, radiation, and temozolomide. Standard of care for GBM has remained unchanged for decades. Gene therapies using both viral and nonviral platforms have the potential to significantly improve outcomes but have faced challenges related to delivery, intratumoral heterogeneity, and immunologic limitations. Observations This review discusses the most recent progress in genetic therapies for gliomas, with a focus on clinical platforms and those nearing clinical translation. Oncolytic and nonlytic replicating viral therapies remain the most clinically advanced, with adeno-associated virus and nonviral systems approaching clinical translation. Treatment efficacy has been variable across trials, platforms, and payloads. Oncolytic herpes simplex virus (G47Δ, teserpaturev) has been conditionally approved for the treatment of gliomas in Japan, while next-generation constructs show a potential association between immunologic activation and survival. Common challenges include the verification and quantification of delivery efficiency, the balance between antivector and antitumor immunity, appropriately designed clinical trials, relevant modeling of vector behavior in the preclinical setting, regulatory clearance, and manufacturing. Conclusions and Relevance Understanding the potential and limitations of gene therapies for gliomas is vital in navigating the path forward for these promising therapies. The future of these treatments will focus on improved clinical trial design with rapid confirmation and tracking of delivery, biomarker feedback and assay optimization, and combination strategies. A focus on delivery platform development can compress iteration cycles and lead to therapeutic benefit for patients with gliomas and other solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaGenetic TherapyBrain NeoplasmsGene Transfer TechniquesHumansAnimalsGene Therapy AgentsOncolytic VirotherapyGenetic Vectors

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California, San Francisco.
  • Department of Neurosurgery, University of Michigan Medical School, Ann Arbor.
  • Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Haddad, A. F., Ramesh, R., Agudelo, J. A. P., Salha, C., Prakash, P., Aghi, S. R., Trippett, J. S., Castro, M. G., & Aghi, M. K. (2026). Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.2131

Vancouver

Haddad AF, Ramesh R, Agudelo JAP, Salha C, Prakash P, Aghi SR, et al. Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.2131

BibTeX
@article{Haddad2026,
  author = {Haddad, Alexander F and Ramesh, Rithvik and Agudelo, Jorge Armando Peña and Salha, Christopher and Prakash, Pranav and Aghi, Shreya R and Trippett, James S and Castro, Maria G and Aghi, Manish K},
  title = {Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma},
  journal = {JAMA Neurology},
  year = {2026},
  doi = {10.1001/jamaneurol.2026.2131}
}
Kostenlos starten →